Show simple item record

dc.contributor.authorDabak, Resat
dc.contributor.authorSimsek, Engin Ersin
dc.contributor.authorTuzun, Sabah
dc.contributor.authorOner, Can
dc.contributor.authorTamer, Ismet
dc.contributor.authorOrbay, Ekrem
dc.contributor.authorBayramicli, Oya
dc.date.accessioned2021-07-09T13:44:26Z
dc.date.available2021-07-09T13:44:26Z
dc.date.issued2020en_US
dc.identifier.citationDABAK R,ŞİMŞEK E. E,TÜZÜN S,ÖNER C,TAMER İ,ORBAY E,BAYRAMİÇLİ O (2020). Effects of Pancreatin therapy on Gastrointestinal Symptoms in Patients with Type 2 Diabetes Mellitus. The anatolian journal of family medicine (Online) , 3(3), 229 - 233. Doi: 10.14744/anatoljfm.2020.25349en_US
dc.identifier.issn2630-5593
dc.identifier.issn2651-3455
dc.identifier.urihttps://hdl.handle.net/20.500.12713/1907
dc.identifier.urihttps://doi.org/10.5505/anatoljfm.2020.25349en_US
dc.description.abstractObjectives: Gastrointestinal symptoms (GIS) are more common in individuals with type 2 diabetes mellitus (DM) in comparison to normal population. This study aimed to evaluate the effects of the pancreatin therapy on the GIS in patients with type 2 DM. Methods: This study included patients with type 2 DM admitted to the Gastroenterology Department between February to July 2017. Age, HbA1c, level of C-peptide, triglyceride, antidiabetic treatments, fecal elastase levels were evaluated in the files of all patients. The GIS of the patients, who were considered to suffer from the exocrine pancreatic insufficiency, including abdominal pain, bloating, constipation and diarrhea were evaluated before and after the 25000 IU pancreatin therapy. Results: The study included 35 patients with type 2 DM, the mean age was 59.1±7.6 years, and 24 (68.6%) of the patients were female. The exocrine pancreatic insufficiency was detected in 1 (2.9%) of the patients. Prior to the pancreatin therapy, 33 (94.3%) of the patients were determined to have abdominal pain, 34 (97.1%) had bloating, 33 (94.3%) had constipation and 32 (91.4%) had diarrhea. After the therapy, 29 (82.9%) of the patients were found to have abdominal pain, 31 (88.6%) had bloating, 31 (88.6%) had constipation and 29 (82.9%) had diarrhea. GIS including abdominal pain, bloating, constipation and diarrhea were decreased after pancreatin treatment (p=0.015, p<0.001, p=0.001 and p=0.024, respectively). Conclusion: GIS in patients with type 2 DM can be treated with pancreatic enzyme replacement therapyen_US
dc.language.isoengen_US
dc.relation.isversionof10.5505/anatoljfm.2020.25349en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAbdominal Painen_US
dc.subjectConstipationen_US
dc.subjectDiarrheaen_US
dc.subjectExocrine Pancreatic Insufficiencyen_US
dc.titleEffects of pancreatin therapy on gastrointestinal symptoms in patients with type 2 diabetes mellitusen_US
dc.typearticleen_US
dc.contributor.departmentİstinye Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.contributor.authorID0000-0001-9596-7203en_US
dc.contributor.institutionauthorTamer, Ismet
dc.identifier.volume3en_US
dc.identifier.issue3en_US
dc.identifier.startpage229en_US
dc.identifier.endpage233en_US
dc.relation.journalThe Anatolian Journal of Family Medicineen_US
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record